bluebird bio Inc

NASDAQ:BLUEUnited States

NASDAQ FSI:E. Delinquent (Issuer missed regulatory filing deadline)

bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with ß-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA was approved by the FDA for the treatment of patients 12 years of age or older with sickle cell disease (SCD) and a history of vaso-occlusive events (VOEs). It is focused on pursuing curative gene therapies.

Contact Information

Headquarters

455 Grand Union BoulevardSOMERVILLE, MA, United States 02145

Phone

339-499-9300

Fax

302-636-5454

Executives

Independent Chairman of the Board

Mark Vachon

President, Chief Executive Officer, Director

Andrew Obenshain

Chief Financial Officer

O. James Sterling

Chief Commercial and Operating Officer

Thomas Klima

Chief Medical Officer

Richard Colvin